Harbin Veterinary Research Institute, CAAS, signed a strategic cooperation agreement with BioEngine. This cooperation is a complementary advantage, strong combination, innovation-driven development

On July 6, 2018, the signing ceremony of the strategic cooperation agreement between Harbin Veterinary Research Institute, CAAS, and Shanghai BioEngine Sci-Tech Co., Ltd. The two sides will work together for the development and application of new products and processes of veterinary biological products through complementary advantages and strong alliances for collaborative innovation. The signing ceremony was attended by Feng Li, Vice Director of Harbin Veterinary Research Institute, Cai Xuehui, Director of the Achievement Transformation Department, Gao Honglei, Vice Minister of the R&D Department, Tan Wensong, Chairman of BioEngine, Lu Yi, General Manager and main executives of BioEngine.

Before the signing ceremony, Chairman Tan Wen Song firstly expressed his warm welcome to the arrival of Vice Director Feng Li of Harbin Veterinary Research Institute and briefly introduced the development situation of BioEngine. As the achievement transformation platform of Prof. Tan's team, the company has been established since the end of 2014, aiming to solve the key and core problems of scale-up, engineering, and industrialization for animal cell expression products (antibodies, virus vaccines, etc.), human stem cells and tissue engineering for biopharmaceutical companies. Through the development of personalized low/serum-free medium design and development, development and establishment of efficient production processes (high density of cell culture, high yield of target products), optimization of bioreactor scaling and intensive optimization of operation, optimization of product quality control and other key technologies and application services, we have established close cooperation with more than 20 domestic leading biopharmaceutical companies in pilot and industrialization technology development. In August 2016, the company completed the first phase of construction, with the technical service and process development capability of serving more than 10 antibody vaccine products and more than 8 antibody vaccine companies at the same time, and built a fully automatic, low-temperature culture medium dry powder production line with an annual capacity of 10 million liters and advanced international level. In 2017, the company was awarded the EU ISO.13485:2016 quality management system certification, becoming the only domestic culture media R&D and manufacturing enterprise that has obtained this certification. Subsequently, Keyu Shi, vice general manager of BioEngine, introduced the performance, operation, and quality management system of the culture media production line in detail and invited Vice President Feng Li and his delegation to have a site visit.

Harbin Veterinary Research Institute, CAAS, has the only significant animal biosafety level 4 facility in China - "National High-Level Biosafety Laboratory for Animal Disease Prevention and Control". Historically, it has made decisive scientific and technological contributions to the control and elimination of "rinderpest", "bovine pneumonia" and "horse-borne poverty" in China, as well as the successful development of a rabbit-weakened vaccine for swine fever. In the 21st century, he made outstanding scientific and technological contributions in the research and prevention, and control of "avian influenza", played a key role in the scientific and technical research and control of "SARS", and made decisive scientific and technological contributions to the prevention and control of "blue ear disease" and viral diarrhea in piglets. The Institute has played an important role in scientific and technical support for the prevention and control of blue ear disease and viral diarrhea of piglets. In the past 70 years since its establishment, the institute has had a strong innovation capability in the source of biological products.

At the signing ceremony, Feng Li, Vice Director of Harbin Veterinary Research Institute, and Tan Wensong, Chairman of the BioEngine, signed the strategic cooperation framework agreement on behalf of both parties. The two sides will further promote the transformation and application of scientific and technological achievements in the direction of veterinary biological products, drive the overall technical level of the veterinary biological products industry, and promote the scientific and technological development of veterinary biological products in China!